Aumolertinib Plus Anlotinib Shows Promise for Untreated EGFR-Mutant NSCLC with CNS Metastases
Key Insights
Combination therapy with aumolertinib (search) plus anlotinib demonstrates significant clinical activity in untreated EGFR (search)-mutant non-small cell lung cancer patients, addressing the critical unmet need for effective CNS-penetrant treatments.
Central nervous system metastases affect over 50% of EGFR (search)-mutant NSCLC patients during disease progression, with 36% presenting with CNS involvement at diagnosis and rates increasing to 54% at five years.
Novel therapeutic approaches including dual EGFR (search)-VEGF (search) pathway inhibition and iron chelation strategies are emerging as promising treatment options for patients with leptomeningeal disease.
The combination of aumolertinib (search) and anlotinib represents a promising therapeutic advance for patients with untreated EGFR (search)-mutant non-small cell lung cancer (NSCLC), particularly those facing the challenge of central nervous system (CNS) metastases. This dual-pathway approach targeting both EGFR and angiogenesis pathways addresses a critical gap in treatment options for a patient population with historically poor outcomes.
CNS Metastases: A Persistent Challenge
Central nervous system metastases remain one of the most formidable obstacles in EGFR (search)-mutant NSCLC management. Recent data from patients treated with first-line osimertinib reveals that approximately 36% of patients present with CNS involvement at the time of metastatic disease diagnosis. This proportion increases dramatically over time, with 54% of patients developing CNS metastases by the five-year mark. Leptomeningeal disease, while rare at presentation, affects about 12% of patients at five years.
Helena Yu, MD, attending physician at Memorial Hospital and research director at Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, emphasized the prognostic significance of these findings during the 2025 World Conference on Lung Cancer. "CNS progression remains a significant unmet need even in the era of highly CNS-penetrant tyrosine kinase inhibitors," Yu noted, highlighting that patients with acquired CNS metastases experience worse survival compared with those presenting with de novo CNS disease.
Dual-Pathway Inhibition Strategy
The combination of aumolertinib (search), a third-generation EGFR (search) tyrosine kinase inhibitor, with anlotinib, a multi-targeting anti-angiogenic agent, represents a rational therapeutic approach. Anlotinib functions as a novel multi-targeting tyrosine kinase inhibitor with demonstrated clinical activity in advanced NSCLC. Previous studies have shown that anlotinib combined with gefitinib can significantly improve proliferation control in EGFR-mutant advanced NSCLC both in vitro and in vivo.
The scientific rationale for this combination stems from the understanding that dual EGFR (search)-VEGF (search) pathway inhibition presents a promising strategy for patients with EGFR-mutant NSCLC. Research has demonstrated that VEGF-A expression correlates with TP53 (search) mutations in non-small cell lung cancer, with implications for antiangiogenesis therapy effectiveness.
Clinical Evidence and Outcomes
The AENEAS trial, a randomized phase III study, demonstrated the superiority of aumolertinib (search) versus gefitinib as first-line therapy for locally advanced or metastatic NSCLC with EGFR (search) exon 19 deletion or L858R mutations. Building on this foundation, the combination approach with anlotinib aims to enhance both systemic and CNS efficacy.
Central nervous system efficacy data from the AENEAS study showed that aumolertinib (search) demonstrated superior CNS penetration compared to gefitinib in patients with untreated, EGFR (search)-mutated, advanced NSCLC. This CNS activity is particularly relevant given that mutation subtype influences prognosis, with patients harboring atypical or uncommon EGFR mutations experiencing worse outcomes when CNS involvement is present.
Addressing Treatment Gaps
Current clinical trial designs often exclude patients with untreated or progressive brain metastases and leptomeningeal involvement, creating significant evidence gaps. Given that over 50% of patients with EGFR (search)-mutant NSCLC ultimately face CNS progression, these exclusions disproportionately impact this population.
To address these limitations, investigators are conducting trials specifically designed for patients with active CNS disease. Recent work with amivantamab plus lazertinib in patients with progressive brain metastases showed systemic response rates of 30% and intracranial responses of 40%, demonstrating meaningful CNS activity comparable to systemic efficacy.
Genomic Insights and Resistance Mechanisms
Efforts to identify genomic determinants of CNS metastasis have revealed intriguing patterns. Comparisons between patients with and without brain metastases identified higher frequencies of CDK11 (search) amplifications and lower frequencies of MYCN (search) amplifications among those with CNS involvement. However, mutational signature analyses have not revealed clear associations with CNS spread, suggesting that epigenetic and expression-level changes, rather than isolated genomic events, may drive CNS tropism.
Understanding resistance mechanisms remains crucial for optimizing treatment strategies. The combination approach with aumolertinib (search) and anlotinib may help overcome some resistance pathways by simultaneously targeting EGFR (search) signaling and tumor angiogenesis.
Future Treatment Paradigms
The integration of anti-angiogenic therapy with EGFR (search) inhibition represents part of a broader evolution in treatment approaches. Novel therapeutic concepts are emerging, including iron chelation strategies for leptomeningeal disease. Research has shown that tumor cells within the leptomeningeal space rely heavily on iron availability, and intrathecal administration of iron chelators has shown promise in preclinical models.
Additionally, the role of radiation therapy in the context of CNS-penetrant TKIs continues to evolve. While guidelines suggest that upfront TKIs can be recommended for small, asymptomatic brain metastases, patients with larger lesions may benefit from combined approaches incorporating radiation therapy.
Clinical Implementation Considerations
The aumolertinib (search) plus anlotinib combination addresses several key clinical needs in EGFR (search)-mutant NSCLC management. The approach provides enhanced CNS penetration while maintaining systemic efficacy, potentially delaying the onset of CNS progression and improving overall outcomes.
Treatment selection considerations include mutation subtype, with exon 19 deletions generally associated with better outcomes compared to L858R mutations when treated with EGFR (search) inhibitors. The combination strategy may help optimize outcomes across different mutation subtypes while providing additional anti-angiogenic benefits.
As the treatment landscape continues to evolve, the aumolertinib (search) plus anlotinib combination represents a significant step forward in addressing the complex challenges of EGFR (search)-mutant NSCLC with CNS involvement, offering hope for improved outcomes in this difficult-to-treat patient population.